Thursday, April 29th | 12-1PM ET
Early R&D poses many questions and challenges when determining if a biotherapeutic enters the portfolio, and if so, what are its design characteristics? Some of the questions include an assessment of unmet medical need, competitive landscape, intellectual property, reimbursement, and difficulties of developability. Applied BioMath Assess is a new, interactive, web-based application that helps project leaders, protein engineers and chemists, and modelers assess the difficulties and risks in developing a therapeutic very early-on in a project. In this webinar, we will demonstrate how project teams are using Applied BioMath Assess to answer key R&D questions, such as:
- How does affinity impact target inhibition? And PK/TMDD if the target is membrane bound?
- How does dosing interval impact inhibition?
- How does target expression, especially in the site of action, impact design criteria?
- How to think about therapeutic index?
Join us to learn more about how this tool can help you design best-in-class properties, get to clinical candidate selection faster, and terminate infeasible projects earlier.
Presented by: John Burke, PhD, Co-Founder, President and CEO of Applied BioMath
You can read more about Dr. John Burke, here.